CTRI/2022/10/046534已完成3 期
rea cream as prophylaxis for Capecitabine induced Hand Foot Syndrome: a Randomized phase 3 trial at a tertiary care hospital in South India
no sponsor0 个研究点目标入组 228 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with gastrointestinal malignancies of breast cancer initiating capecitabine treatment at a dose of at least 1000mg/m2 twice daily as monotherapy or combination therapy, ECOG PS less than 3, adequate bone marrow function
排除标准
- •Patients with any dermatological toxicity other than alopecia that has not resolved, creatinine clearance of <30ml/min as per Cockcroft gault formula
研究者
相似试验
已完成
4 期
Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.stage III colon cancer including RS cancerJPRN-UMIN000001444KSCC92
已完成
不适用
acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal InsufficiencyRenal insufficiencyUrological and Genital DiseasesISRCTN43635237Academic Medical Centre (AMC) (Netherlands)246
进行中（未招募）
不适用
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma, a randomised phase III study (CAIRO3 study) - CAIRO3Advanced colorectal carcinomaEUCTR2006-006657-27-NLDutch Colorectal Cancer Group
进行中（未招募）
不适用
A study on neoadjuvant chemoradiotherapy with capecitabine in locally advanced rectal cancer.Clinically diagnosed and histopathologically proved adenocarcinoma of rectum.TCTR20180516003Bangabandhu Sheikh Mujib Medical University140
Unknown
1 期
MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITYDermatitis, Adverse Drug ReactionNCT02036957Basque Health Service86